Inventor · disambiguated record
Ross Fulton
Also filed as: FULTON ROSS · FULTON ROSS B · FULTON ROSS BANE
5 granted patents·15 pending applications·13 citations·filing 2016–2025
75Inventor score
Files withHIBERCELL INC8BIOTHERA INC5AKAGERA MEDICINES INC4MERRIMACK PHARMACEUTICALS INC2HIFIBIO INC1
Top patents by PatentIndex Score
20 records- 0196US12064479B2Lipid nanoparticles for delivery of nucleic acids and methods of use thereofAKAGERA MEDICINES INC·Filed 2023·Granted Aug 20, 2024·5 cites·28 claims
- 0291US12331264B2Lipid nanoparticles for delivery of nucleic acids and methods of use thereofAKAGERA MEDICINES INC·Filed 2022·Granted Jun 17, 2025·1 cites·20 claims
- 0386US10111901B2Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentBIOTHERA INC·Filed 2016·Granted Oct 30, 2018·4 cites·19 claims
- 0484US10111900B2β-glucan methods and compositions that affect the tumor microenvironmentBIOTHERA INC·Filed 2016·Granted Oct 30, 2018·3 cites·20 claims
- 0582US2025009782A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 0682US2024325525A1Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use ThereofAKAGERA MEDICINES INC·Filed 2024·Application pending·0 cites
- 0781US2025114392A1Beta-glucan in combination with anti-cancer agents affecting the tumor micrenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 0880US2024350528A1Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentHIBERCELL INC·Filed 2023·Application pending·0 cites
- 0979US2025114391A1Beta-glucan methods and compositions that affect the tumor microenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 1074US2023172967A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2022·Application pending·0 cites
- 1173US2022117998A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1268US2022047620A1Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1367US2021283169A1Beta-glucan methods and compositions that affect the tumor microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1463US2019060350A1Beta-glucan methods and compositions that affect the tumor microenvironmentBIOTHERA INC·Filed 2018·Application pending·0 cites
- 1562US2019022129A1Beta-glucan immunotherapies affecting the immune microenvironmentBIOTHERA INC·Filed 2017·Application pending·0 cites
- 1662US2019060351A1Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentBIOTHERA INC·Filed 2018·Application pending·0 cites
- 1756US2025387462A1Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infectionsAKAGERA MEDICINES INC·Filed 2025·Application pending·0 cites
- 1852US12435151B2Anti-TNFR2 antibodies and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2020·Granted Oct 7, 2025·0 cites·16 claims
- 1950US2025019451A1Anti-ccr8 antibodies and uses thereofHIFIBIO INC·Filed 2022·Application pending·0 cites
- 2043US2021371537A1Anti-tnfr2 antibodies and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ross Fulton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →